

Prostate Product References



Da Silva MHA, De Souza DB. Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. *Res Rep Urol*.

2019;11:1-8[SEP] <https://doi.org/10.2147/RRU.S155609>

Christudoss, P., Selvakumar, R., Fleming, J. J., & Gopalakrishnan, G. (2011). Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma.

Indian journal of urology : IJU : journal of the Urological Society of India, 27(1), 14–18.

<https://doi.org/10.4103/0970-1591.78405>

Alhakamy, N. A., Fahmy, U. A., & Ahmed, O. (2019). Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation. *Pharmaceutics*, 11(12), 640.

<https://doi.org/10.3390/pharmaceutics11120640>

Hong, H., Kim, C. S., & Maeng, S. (2009). Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. *Nutrition research and practice*, 3(4), 323–327. <https://doi.org/10.4162/nrp.2009.3.4.323>

Ahmed, M., Prasad, J., Gill, H., Stevenson, L., & Gopal, P. (2007). Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. *Journal of Nutrition Health and Aging*, 11(1), 26.

Mahdi Mirahmadi, Shayan Azimi-Hashemi, Ehsan Saburi, Hossein Kamali, Mandana Pishbin, Farzin Hadizadeh, Potential inhibitory effect of lycopene on prostate cancer, *Biomedicine & Pharmacotherapy*, Volume 129, 2020, 110459, ISSN 0753-3322,

<https://doi.org/10.1016/j.biopha.2020.110459>.

<https://www.sciencedirect.com/science/article/pii/S0753332220306521>)

- Bonnar-Pizzorno, R. M., Littman, A. J., Kestin, M., & White, E. (2006). Saw palmetto supplement use and prostate cancer risk. *Nutrition and cancer*, 55(1), 21–27. https://doi.org/10.1207/s15327914nc5501_3
- Suzuki, M., Ito, Y., Fujino, T., Abe, M., Umegaki, K., Onoue, S., Noguchi, H., & Yamada, S. (2009). Pharmacological effects of saw palmetto extract in the lower urinary tract. *Acta pharmacologica Sinica*, 30(3), 227–281. <https://doi.org/10.1038/aps.2009.1>
- Kwon Y. (2019). Use of saw palmetto (*Serenoa repens*) extract for benign prostatic hyperplasia. *Food science and biotechnology*, 28(6), 1599–1606. <https://doi.org/10.1007/s10068-019-00605-9>
- Tiwari RK. Guo L. Bradlow HL. Telang NT. Osborne MP. Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. *J Natl Cancer Inst*. 1994;86:126–131.
- Sepkovic DW. Bradlow HL. Bell M. Quantitative determination of 3,3'-diindolylmethane in the urine of individuals receiving indole-3-carbinol. *Nutr Cancer*. 2002;41:57–63.
- Sepkovic DW. Bradlow HL. Bell M. Quantitative determination of 3,3'-diindolylmethane in the urine of individuals receiving indole-3-carbinol. *Nutr Cancer*. 2002;41:57–63.
- Li Y. Wang Z. Kong D. Murthy S. Dou QP. Sheng S. Reddy GP. Sarkar FH. Regulation of FOXO3a/ β catenin/GSK-3 β signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. *J Biol Chem*. 2007;282:21542–21550.
- Rahman KM. Ali S. Aboukameel A. Sarkar SH. Wang Z. Philip PA. Sakr WA. Raz A. Inactivation of NF- κ B by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. *Mol Cancer Ther*. 2007;6:2757–2765.
- Cui, Y., Winton, M. I., Zhang, Z. F., Rainey, C., Marshall, J., De Kernion, J. B., & Eckhert, C. D. (2004). Dietary boron intake and prostate cancer risk. *Oncology reports*, 11(4), 887–892.
- Gonzalez, A., Peters, U., Lampe, J. W., & White, E. (2007). Boron intake and prostate cancer risk. *Cancer causes & control : CCC*, 18(10), 1131–1140. <https://doi.org/10.1007/s10552-007-9052-2>
- Gallardo-Williams, M. T., Chapin, R. E., King, P. E., Moser, G. J., Goldsworthy, T. L., Morrison, J. P., & Maronpot, R. R. (2004). Boron supplementation inhibits the growth and local

expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. *Toxicologic pathology*, 32(1), 73–78. <https://doi.org/10.1080/01926230490260899>

Demark-Wahnefried, W., Polascik, T. J., George, S. L., Switzer, B. R., Madden, J. F., Ruffin, M. T., 4th, Snyder, D. C., Owzar, K., Hars, V., Albala, D. M., Walther, P. J., Robertson, C. N., Moul, J. W., Dunn, B. K., Brenner, D., Minasian, L., Stella, P., & Vollmer, R. T. (2008). Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 17(12), 3577–3587. <https://doi.org/10.1158/1055-9965.EPI-08-0008>

Saarinen, N. M., Wärrä, A., Airio, M., Smeds, A., & Mäkelä, S. (2007). Role of dietary lignans in the reduction of breast cancer risk. *Molecular nutrition & food research*, 51(7), 857-866.

Mason, J. K., & Thompson, L. U. (2014). Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer?. *Applied Physiology, Nutrition, and Metabolism*, 39(6), 663-678.

Webb, A. L., & McCullough, M. L. (2005). Dietary lignans: potential role in cancer prevention. *Nutrition and cancer*, 51(2), 117-131.

Cho, H. J., Park, S. Y., Kim, E. J., Kim, J. K., & Park, J. H. (2011). 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. *Molecular carcinogenesis*, 50(2), 100–112. <https://doi.org/10.1002/mc.20698>

Wang, C., & Youle, R. J. (2009). The role of mitochondria in apoptosis*. *Annual review of genetics*, 43, 95–118. <https://doi.org/10.1146/annurev-genet-102108-134850>

Wang, C., & Youle, R. J. (2009). The role of mitochondria in apoptosis*. *Annual review of genetics*, 43, 95–118. <https://doi.org/10.1146/annurev-genet-102108-134850>

Zhang, W. W., Feng, Z., & Narod, S. A. (2014). Multiple therapeutic and preventive effects of 3,3'-diindolylmethane on cancers including prostate cancer and high grade prostatic

intraepithelial neoplasia. *Journal of biomedical research*, 28(5), 339–348.

<https://doi.org/10.7555/JBR.28.20140008>

Shenouda, N. S., Sakla, M. S., Newton, L. G., Besch-Williford, C., Greenberg, N. M., MacDonald, R. S., & Lubahn, D. B. (2007). Phytosterol *Pygeum africanum* regulates prostate cancer in vitro and in vivo. *Endocrine*, 31(1), 72–81. <https://doi.org/10.1007/s12020-007-0014-y>

Wilt, T., Ishani, A., Mac Donald, R., Rutks, I., & Stark, G. (2002). *Pygeum africanum* for benign prostatic hyperplasia. *The Cochrane database of systematic reviews*, 1998(1), CD001044. <https://doi.org/10.1002/14651858.CD001044>

Wilt, T., Ishani, A., MacDonald, R., Stark, G., Mulrow, C., & Lau, J. (2000). Beta-sitosterols for benign prostatic hyperplasia. *The Cochrane database of systematic reviews*, (2), CD001043. <https://doi.org/10.1002/14651858.CD001043>

Klippel, K. F., Hiltl, D. M., & Schipp, B. (1997). A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. *British journal of urology*, 80(3), 427–432.

Wertz, K., Siler, U., & Goralczyk, R. (2004). Lycopene: modes of action to promote prostate health. *Archives of biochemistry and biophysics*, 430(1), 127–134. <https://doi.org/10.1016/j.abb.2004.04.023>